Zobrazeno 1 - 10
of 539
pro vyhledávání: '"Lale, Tokgozoglu"'
Autor:
Francesco Perone, Marco Bernardi, Alban Redheuil, Dario Mafrica, Edoardo Conte, Luigi Spadafora, Fiona Ecarnot, Lale Tokgozoglu, Carlos G. Santos-Gallego, Sergio Emanuel Kaiser, Federica Fogacci, Annabelle Sabouret, Deepak L. Bhatt, Francesco Paneni, Maciej Banach, Raul Santos, Giuseppe Biondi Zoccai, Kausik K. Ray, Pierre Sabouret
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 17, p 5563 (2023)
Optimal risk assessment for primary prevention remains highly challenging. Recent registries have highlighted major discrepancies between guidelines and daily practice. Although guidelines have improved over time and provide updated risk scores, they
Externí odkaz:
https://doaj.org/article/0f1bbc5a72c348d188c854a42c12e750
Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis
Autor:
Duygu Kocyigit, Francesca Zimetti, Kadri M. Gurses, Ilaria Zanotti, Cinzia Marchi, Marcus Ståhlman, Jan Borén, Hande Canpinar, Mehmet F.T. Soyal, Dicle Guc, Tuncay Hazirolan, Necla Ozer, Lale Tokgozoglu
Publikováno v:
Atherosclerosis Plus, Vol 44, Iss , Pp 18-24 (2021)
Background and aims: Cholesterol efflux capacity is a functional property of high-density lipoproteins (HDL) reflecting the efficiency of the atheroprotective reverse cholesterol transport process in humans. Its relationship with calcific aortic valv
Externí odkaz:
https://doaj.org/article/894bef3bc2e144078124fba7ff9125ec
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 25, Iss 2, Pp 242-269 (2020)
Cardiovascular disease (CVD) is the leading cause of death. Although once considered merely as a lipid storage disease, studies indicate the role of inflammation in initiation and progression of atherosclerotic CVD, as well as the development of thro
Externí odkaz:
https://doaj.org/article/20c8dc3ba9624585ba558fc2fc8ceb22
Autor:
Meral Kayikcioglu, Lale Tokgozoglu
Publikováno v:
Pharmaceuticals, Vol 16, Iss 1, p 64 (2022)
Homozygous familial hypercholesterolemia (HoFH) is the rare form of familial hypercholesterolemia causing extremely high low-density lipoprotein cholesterol (LDL-C) levels, leading to atherosclerotic cardiovascular disease (ASCVD) in the first decade
Externí odkaz:
https://doaj.org/article/97690322e7614b4b9409090f368cbcad
Autor:
Sevda Aygun, Lale Tokgozoglu
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 23, p 7249 (2022)
The dyslipidemia guidelines of the three major societies have been revised recently in light of new evidence. LDL-C is the primary target in the ESC, AHA/ACC/Multisociety and Canadian Cardiovascular Society (CCS) guidelines. These guidelines uniforml
Externí odkaz:
https://doaj.org/article/575e4d1295914b5db7c56244e457b8cc
Publikováno v:
American Journal of Preventive Cardiology, Vol 6, Iss , Pp 100184- (2021)
Turkey, like many countries, is facing a growing burden of non-communicable disease (NCD)s and is among the countries with high cardiovascular mortality in Europe. Moreover, Turkey currently has the highest rate of premature cardiovascular disease (C
Externí odkaz:
https://doaj.org/article/548e84ba612d4e61a3b8fd58b48b0108
Autor:
Meral Kayıkçıoğlu, Lale Tokgozoglu, Mustafa Kılıçkap, Hüseyin Göksülük, Doruk Karaaslan, Necla Özer, Adnan Abacı, Mehmet Birhan Yılmaz, Cem Barçın, Kenan Ateş, Fahri Bayram, Mahmut Şahin, Dilek Ural
Publikováno v:
Türk Kardiyoloji Derneği Arşivi, Vol 46, Iss 7, Pp 556-574 (2018)
Objective: Dyslipidemias, primarily hypercholesterolemia, are independent and strong predictors of cardiovascular (CV) events. The frequency of dyslipidemia is very important in terms of determining CV prevention policies. In order to determine the u
Externí odkaz:
https://doaj.org/article/3136d4ae869141c6b66af87ee4d158be
Publikováno v:
American Journal of Preventive Cardiology, Vol 4, Iss , Pp 100128- (2020)
Objectives: The coronavirus-disease-2019 (COVID-19) pandemic has led to the restructuring of health-services to prioritize the treatment of COVID-19. The severe restrictions on daily life affected the management of chronic diseases. Patients with a p
Externí odkaz:
https://doaj.org/article/fd673d4d1bbc46c4a88edeacdfbf7dcf
Autor:
Carl E. Orringer, Lale Tokgozoglu, Kevin C. Maki, Kausik K. Ray, Joseph J. Saseen, Alberico L. Catapano
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 21 (2020)
Despite consensus that excessive circulating concentrations of apoB‐lipoproteins is a key driver for the atherosclerotic process and that treatments that low‐density lipoprotein cholesterol lowering by up‐regulation of low‐density lipoprotein
Externí odkaz:
https://doaj.org/article/e0fa4fd9f8914ff2bb9030c588345bf2
Publikováno v:
Current Atherosclerosis Reports. 24:995-1004
Purpose of Review Since the clinical benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density lipoprotein-cholesterol (LDL-C) to unprecedentedly low levels, it becomes of interest to inve